RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2012; 137(49): 2540-2542
DOI: 10.1055/s-0032-1327285
DOI: 10.1055/s-0032-1327285
Endokrinologie und Diabetologie | Commentary
Endokrinologie
Neue Entwicklungen bei Hypophysenerkrankungen
New developments in pituitary diseasesWeitere Informationen
Publikationsverlauf
Publikationsdatum:
27. November 2012 (online)
![](https://www.thieme-connect.de/media/dmw/201249/lookinside/thumbnails/10.1055-s-0032-1327285-1.jpg)
-
Literatur
- 1 Bleicken B, Hahner S, Loeffler M et al. Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 2010; 72: 297-304
- 2 Colao A, Petersenn S, Newell-Price J et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med 2012; 366: 914-924
- 3 Elenkova A, Shabani R, Kalinov K et al. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. Eur J Endocrinol 2012; 167: 17-25
- 4 Famini P, Maya MM, Melmed S. Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients. J Clin Endocrinol Metab 2011; 96: 1633-1641
- 5 Fenske W, Quinkler M, Lorenz D et al. Copeptin in the differential diagnosis of the polydipsia-polyuria syndrome – revisiting the direct and indirect water deprivation tests. J Clin Endocrinol Metab 2011; 96: 1506-1515
- 6 Fernandez-Balsells MM, Murad MH, Barwise A et al. Natural history of nonfunctioning pituitary adenomas and incidentalomas. J Clin Endocrinol Metab 2011; 96: 905-912
- 7 Fleseriu M, Biller BM, Findling JW et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab 2012; 97: 2039-2049
- 8 Freda PU, Beckers AM, Katznelson L et al. Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 894-904
- 9 Hahner S, Loeffler M, Bleicken B et al. Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. Eur J Endocrinol 2010; 162: 597-602
- 10 Halperin I, Aller J, Varela C et al. No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma. Clin Endocrinol (Oxf) 2012; 77: 275-280
- 11 Liu X, Kano H, Kondziolka D et al. Gamma knife stereotactic radiosurgery for drug resistant or intolerant invasive prolactinomas. Pituitary 2012; Feb 3. [Epub ahead of print]
- 12 Melmed S, Casanueva FF, Hoffman AR et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 273-288
- 13 Molitch ME. Prolactinoma in pregnancy. Best Pract Res Clin Endocrinol Metab 2011; 25: 885-896
- 14 Morgenthaler NG, Struck J, Jochberger S et al. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 2008; 19: 43-49
- 15 Ortiz LD, Syro LV, Scheithauer BW et al. Temozolomide in aggressive pituitary adenomas and carcinomas. Clinics (Sao Paulo) 2012; 67 (Suppl. 01) 119-123
- 16 Petersenn S, Quabbe HJ, Schofl C et al. The rational use of pituitary stimulation tests. Dtsch Arztebl Int 2010; 107: 437-443
- 17 Schneider HJ, Kosilek RP, Gunther M et al. A novel approach to the detection of acromegaly: accuracy of diagnosis by automatic face classification. J Clin Endocrinol Metab 2011; 96 (07) 2074-80
- 18 Tritos NA, Biller BM, Swearingen B. Management of Cushing disease. Nat Rev Endocrinol 2011; 7: 279-289
- 19 van der Lely AJ, Biller BM, Brue T et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 2012; 97: 1589-1597
- 20 Whitelaw BC, Dworakowska D, Thomas NW et al. Temozolomide in the management of dopamine agonist-resistant prolactinomas. Clin Endocrinol (Oxf) 2012; 76: 877-886